|
Welcome to InSite Issue 6 in which you will find links to the presentations given at the Biennial 2008 meeting held in September in Bath, UK. If you would like to contribute to the Healthcare Professional Viewpoint section or offer suggestions to make the content more valuable for you then please get in touch. Kind regards |
|
2009 Issue 6 |
|
International Myeloma Workshop (IMW) Consensus Panel Reports were presented on Saturday 28th February at IMW in Washington. They included discussion of Guidelines for the Uniform Reporting of Clinical Trials and Panel 3: Guidelines for standard investigative workup. They can be viewed by following the links below.
Panel 1: Guidelines for the Uniform Reporting of Clinical Trials View at: http://www.mw-delhi09.com/spargoDocs/Consensuspanelone.pdf
Panel 3: Guidelines for standard investigative workup View at: http://www.mw-delhi09.com/spargoDocs/Consensuspanelthree.pdf |
|
Publications and updated guidelines |
|
Exhibitions and Meetings - Catching up and planning ahead |
|
If you have a friend or colleague who you feel would benefit from receiving this newsletter then please forward this to them.
Received this from a colleague? We need your permission to send you future issues - please Click here to register. |
|
Refer a friend/colleague |
|
The Binding Site Ltd |
|
Þ Review of publications and conferences Þ More news on Hevylite |
|
What’s in Issue 7 |
|
Spotlight Review. International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders Dispenzieri et al Leukemia (2009) 23,215-224; doi:10.1038/leu.2008.307
Please click here to request your copy (Code MKG492).
The key recommendations are:-
1. ‘The serum FLC assay in combination with serum PEL and serum IFE is sufficient to screen for pathological monoclonal plasmaproliferative disorders other than AL which requires all the serum tests as well as 24 h urine IFE.’ 2. ‘The serum FLC assay should be measured at diagnosis for all patients with MGUS, smoldering or active multiple myeloma. Solitary plasmacytoma and AL amyloidosis.’ 3. ‘Serial FLC ascertainment should be routinely performed in patients with AL amyloidosis and multiple myeloma patients with oligosecretory disease.’ 4. ‘It should also be done in all patients who have achieved a CR to determine whether they have attained a stringent CR.’ |
|
New guidelines now available as reprints |
|
Click to view the agenda:
Ashford, Kent - May 12 Edinburgh - May 15
5 CPD points awarded by Royal College of Pathologists at each meeting. 7 CPD points awarded by IBMS at each meeting.
To apply for a place at one of these seminars please email us with your full contact details quoting UK Freelite and the city you wish to attend. Please email us at roadshow@bindingsite.co.uk
Due to restrictions at the venue we can only accept delegates up to the fire and safety limits. If you do not receive a confirmation email then we are very sorry but you have been unsuccessful this time.
The closing date for requesting a place is 27 April 2009.
If we find we are oversubscribed we may need to get in contact with you to ask if you could limit the number of participants from your department in order to accommodate as many departments as possible. |
|
Don’t forget to visit our webinars page regularly to view webinars held in the USA by Binding Site Inc. We have recently added a webinar entitled: Strategies for Optimizing Outcomes in Myeloma and Other Monoclonal Gammopathies, presented by Dr Maurizio Zangari, Professor of Hematology and Oncology, and Director of Experimental Therapeutics at the University of Utah School of Medicine. |
|
Webinars |
|
Healthcare professional viewpoint |
|
Guillermo Herrera, MD is Professor and Chairman in the Department of Pathology at Saint Louis University. His clinical specialties include effects of monoclonal light chains on the kidney and growth factors in the kidney and soft tissue tumors. His expertise includes pathogenesis of AL amyloidosis, glomerular injury in plasma cell dyscrasia and chronic renal transplant rejection. Click here to read an interview with Guillermo Herrera. |
|
The XIIth International Myeloma Workshop, Washington DC, USA, 26 February - 1 March 2009
The XIIth International Myeloma Workshop was held in Washington, D.C. from 26 February - 1 March 2009. This meeting is a prestigious biannual event that brings together myeloma experts from around the world. The scientific program is designed to stimulate debate and discussion among experts and to advance our understanding of the disease biology and therapy. The program included presentations on molecular and cell signalling changes associated with myeloma cells growth and survival, new targets and novel therapies, and discussion of current and future phase I, II and III studies. There was also discussion of guidelines related to diagnosis, prognosis and therapy of Myeloma.
Binding Site had a stand and we also hosted a breakfast symposium on the last day. Additionally 17 posters were presented that featured Freelite and a further 6 discussed Hevylite. Thank you to all of you who visited us on the stand, attended the symposium or viewed the posters. The symposium, attended by approximately 350 delegates, brought the audience up to date regarding Freelite, introduced Hevylite, discussed the Gambro HCO1100 high cut-off membrane and ensured all are aware of the recommendations made in the International Myeloma Working Group Guidelines for serum free light chain analysis in multiple myeloma and related disorders. Jo Bradwell, Graham Mead and Angela Dispenzieri delivered the talks and Stephen Harding chaired the symposium.
The International Myeloma Foundation webcast live from the meeting and have archived the main session talks. You can access the talks on their website by clicking here.
|
|
International Marketing Manager - Freelite™ & Hevylite™ |
|
Find out more about serum free light chains at www.freelite.co.uk |
|
If you no longer wish to receive this newsletter, please Click here to unsubscribe. |
|
Previous editions of InSite can also be read online here. |
|
If you were unable to make it to this meeting or want to remind yourself of what was presented, a number of talks are available to view and listen to here. |
|
Presentations from the Biennial 2008 Conference in Bath |
|
Join our UK Roadshows entitled: ‘Spotlite 2009: Recent advances in the management of Free Light Chain Disease’ |
|
Euromedlab 7-11 June 2009, Innsbruck, Austria Please visit our workshop at Euromedlab, June 10th, 15:30 - 16:30, Room Brussel |
|
Serum Free Light Chain Analysis (plus Hevylite) Fifth Edition by A.R Bradwell? If not click here to request a copy. This 312 page latest edition, written by Prof A.R. Bradwell, includes thought provoking new information on renal applications of serum free light chain (FLC) assays, new case studies and an introduction to the new Hevylite™ assays due to be launched later in 2009. |
|
Do you have your own copy of... |
|
World Congress of Nephrology 22-26 May 2009, Milan, Italy |
|
Session title: Recent advances in the management of Free Light Chain Disease
Agenda
Chairman: Prof. Dr. med. Johannes Drach, Medizinische Universität, Wien, Austria
Application and clinical significance of serum free light chain testing - Prof. Drach, Medizinische Universität, Wien, Austria
The new International Myeloma Working Group Myeloma Guidelines and how they impact the laboratory - Dr. Jerry Katzmann, Mayo Clinic, US
Treatment of acute renal failure secondary to multiple myeloma with chemotherapy and extended high cut-off hemodialysis - Dr. Paul Cockwell, University Hospital, Birmingham, UK. |
|
If you are having trouble viewing this message, please click here |